Breast Cancer
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Details
ClinicalTrials.gov ID:
NCT06312176
Diagnosis Type:
NA
USOR Number:
- Address
,
P: